Northwestern Medicine investigators continue to study the COVID-19 pandemic, from the biological mechanisms of disease and infection patterns to the pandemic’s impact on women and sexual and gender minorities.
A recent Northwestern Medicine study found global efforts to track variants grossly underreported a probable variant of concern, Eta, circulating in Nigeria in early 2021.
The first omicron BA.2 subvariant case has been detected in Illinois by Northwestern Medicine’s Center for Pathogen Genomics and Microbial Evolution (CPGME).
A new study has identified naturally occurring nano-sized particles that can block infection from broad strains of SARS-CoV-2 virus in preclinical studies.
Of the more than 20 episodes of the medical school’s Breakthroughs podcast produced in 2021, the most popular ranged across specialties from gastroenterology to nanotechnology. Listen to the top five episodes of the year and earn Continuing Medical Education credit.
Northwestern Medicine scientists continue to tackle every facet of the COVID-19 pandemic, from investigating coronavirus vaccines’ potential for providing immunity against similar coronaviruses to developing novel rapid antigen-based tests and examining disparities in COVID-19 case and mortality rates in Chicago.
An interdisciplinary team of Northwestern Medicine investigators led by Karen Ridge, PhD, has been awarded a $14 million grant from the National Heart, Lung, and Blood Institute to study the mechanisms that promote lung tissue repair in patients with severe viral pneumonia.
Coronavirus vaccines and prior coronavirus infections can provide broad immunity against other, similar coronaviruses, paving the way for future universal coronavirus vaccines.
The growing number of patients suffering from long-term complications of COVID-19 has spurred the creation of Northwestern Medicine’s Comprehensive COVID-19 Center, which provides coordinated, multidisciplinary care.
A new study shows that two months after the second Pfizer/Moderna vaccination, antibody response decreases 20 percent in adults with prior cases of COVID-19 and examines how current vaccines resist emerging variants.